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Antimicrobial, antimalarial and cytoxicity activities of constituents of a
Bhutanese variety of Ajania nubigena
Abstract

An investigation of the essential oil (EO) and the crude MeOH extract of a Bhutanese variety of Ajania
nubigena using GC/GC-MS and NMR found the following: a) one kg of the dried plant material contained
0.7% w/w EO; b) 44 of the 53 GC-FID peaks of the EO were identified with (3R,6R)-linalool oxide acetate
(75.8 %) as the major constituent (chemotype II) and chamazulene as a new sub-chemotype; c) purification
of the EO furnished (3R,6R)-linalool oxide acetate (1), chamazulene (2),
(E)-2-(2,4-hexadiynylidene)-1,6-dioxaspiro[4,4]non-3-ene (3), and
(Z)-2-(2,4-hexadinylidene)-1,6-dioxaspiro[4,4]non-3-ene (4); d) from the crude MeOH extract, four
flavonoid compounds: 1-(4-hydroxyphenyl)propan-1-one (5), oxyanin B (6), luteolin (7) (major) and the
luteolin-7-O-�- D-glucoside (8) were isolated; e) among the EO and pure compounds tested for biological
activities, compound 7 exhibited a broad range of moderate antiplasmodial, cytoxicity and antimicrobial
activities; c) compound 8 showed significant in vitro antiplasmodial activity against P. falciparum strains
TM4/8.2 and K1CB1 (multidrug resistant strain) and was identified as a potential antimalarial scaffold; and
f) the in vitro antimicrobial and cytotoxicity activities were in alignment with the traditional medical uses of
this plant and thus substantiate its use in Bhutanese traditional medicine.
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An investigation of the essential oil (EO) and the crude MeOH extract of a Bhutanese variety of Ajania nubigena using GC/GC-MS and NMR found the
following: a) one kg of the dried plant material contained 0.7% w/w EO; b) 44 of the 53 GC-FID peaks of the EO were identified with (3R,6R)-linalool oxide
acetate (75.8 %) as the major constituent (chemotype II) and chamazulene as a new sub-chemotype; c) purification of the EO furnished (3R,6R)-linalool oxide
acetate (1), chamazulene (2), (E)-2-(2,4-hexadiynylidene)-1,6-dioxaspiro[4,4]non-3-ene (3), and (Z)-2-(2,4-hexadinylidene)-1,6-dioxaspiro[4,4]non-3-ene (4);
d) from the crude MeOH extract, four flavonoid compounds: 1-(4-hydroxyphenyl)propan-1-one (5), oxyanin B (6), luteolin (7) (major) and the luteolin-7-O-βD-glucoside (8) were isolated; e) among the EO and pure compounds tested for biological activities, compound 7 exhibited a broad range of moderate
antiplasmodial, cytoxicity and antimicrobial activities; c) compound 8 showed significant in vitro antiplasmodial activity against P. falciparum strains TM4/8.2
and K1CB1 (multidrug resistant strain) and was identified as a potential antimalarial scaffold; and f) the in vitro antimicrobial and cytotoxicity activities were
in alignment with the traditional medical uses of this plant and thus substantiate its use in Bhutanese traditional medicine.
Keywords: Ajania nubigena, esential oil, flavonoid, Bhutanese traditional medicine, antimalarial, antimocrobial, cytotoxicity.

Ajania is a relatively small genus of the family Asteraceae with
only 28-40 species which are found in Russia and Asia (Bhutan,
Nepal, India, Tibet, China and Japan) [1-3]. In Bhutan, only two
Ajania species: A. nubigena and A. myriantha have been reported
[4]. A. nubigena is locally known as m.khan-d.kar and contributes
to the preparation of at least four important multi-ingredient
Essential Traditional Medicine Drugs (ETMDs) or polyherbal
formulations [5] including a popular product called b.dud-rtsi ngalum (Five Herbal Ambrosia). ‘Five Herbal Ambrosia’ is used in spa
related health care practices. As an individual plant, it is used in the
Bhutanese traditional medicine (BTM) as incense, vulnerary,
expectorant, styptic and anti-epistaxis and also for treating
abscesses, swelling of limbs, tumor and kidney infections [6].
A. nubigena has been ascribed different synonyms/basonyms as
Artemisia nubigena, Dendranthema nubigenum, Chrysanthemum
nubigenum and Tanacetum nubigenum [7]. Varieties of this plant
growing in different regions of India, including Kumaon, Garwal,
Uttarakhand and Uttar Pradesh, have been classified based on three
main chemotypes of their essential oils (EO) [8-12]. Chemotype I
contained bornyl acetate (39.7%) as a major marker constituent of
the EO while chemotype II and III contained (3R,6R)-linalool oxide
acetate (69.4%) and (-)-cis-chrysanthenol (37.0%) as their principal
components, respectively [8].
While the Indian varieties of A. nubigena (ascribed under the
basonym Tanacetum nubigenum) have been studied [8-12], a
Bhuatanese variety growing in the extreme vegetation and climatic
conditions of the Bhutan Himalaya has not been investigated for its
phytochemicals or biological activities, especially for antimalarial
activity and cytotoxicity. Moreover, these studies on the Indian
varieties of A. nubigena reported the analysis of the EO of the fresh
plant material, which is contrary to the manner in which this plant is
used by the local people in India, Nepal and Bhutan, who use it in
its dried form. Differences in the quality and the chemical

constituents of these differently prepared plant samples were thus
expected. Therefore, in order to scientifically validate the Bhutanese
ethnopharmacological uses of this plant in its authentic manner of
usage, we initially studied the antimalarial, antimicrobial and
cytotoxicity activities of various crude solvent extracts of this dried
plant material [6]. These preliminary studies indicated that the plant
was a good source of antimalarial and antimicrobial agents. This
encouraged us to investigate the chemical components of the EO
and the methanol extract of the dried plant material. The EO and the
isolated major phytochemicals were assessed for their antimalarial,
antimicrobial and cytotoxic activities and the results are discussed
here for the first time.
The hydrodistilled essential oil (0.7% w/w or 7 g/1000 g dry
weight) component was analysed using GC and GC-MS which
detected 53 constituent peaks of the chromatographable fraction of
the total injected oil (Table 1). Of these, 44 compounds were
identified with (3R,6R)-linalool oxide acetate (75.8%) as the major
constituent, followed by 6-ethenyldihydro-2,2,6-trimethyl-2Hpyran-3(4H)-one (4.6%), β-farnesene (2.9%), epoxylinalol (2.8%),
germacrene D (1.4%), bisabolol oxide A (1.2%), chamazulene
(1%),
(E)-2-(2,4-hexadiynylidene)-1,6-dioxaspiro[4,4]non-3-ene
(1%), and (Z)-2-(2,4-hexadiynylidene)-1,6-dioxaspiro[4,4]non-3ene (1%).
The percent contents of the EO were determined on the basis of
their FID responses on GC. All the identified compounds are
presented in Table 1.
Table 1: EO constituents of aerial parts of Ajania nubigena.
Compound name

KI†

α-pinine
β-citrollene
1-methylpentyl hydroperoxide
benzaldehyde
cis-linalool oxide

934
947
949
957
1090

% oil
0.1
0.1
0.1
0.1
0.3

2

β-linalool
6-ethenyldihydro-2,2,6-trimethyl-2H-pyran-3(4H)-one
L-pinocarveol
L-camphor
pinocarvone
(-)-borneol
epoxylinalol
homoveratrole
(3R,6R)-linalool oxide acetate
eugenol
α-copaene
aromadendrene
β-farnesene
unidentified
5-ketobornyl acetate
seychellene
germacrene D
patchoulene
unidentified
α-muurolene
α-bisabolene
epiglobulol
unidentified
(Z)-α-bisabolene epoxide*
sapathulenol
caryophyllene oxide
isoaromadendrene epoxide
unidentified
unidentified
6-hexadecen-4-yne
unidentified
cubenol
unidentified
4-methylene-1-methyl-2-(2-methyl-1-propen-1-yl)-1-vinylcycloheptane*
eudesm-4(14)-en-11-ol
τ-cadinol
β-santalol
octahydro-4a,8a-dimethyl-7-(1-methylethyl), 1(2H)napthalenone
unidentified
6-isopropenyl-4,8a-dimethyl-1,2,3,5,6,7,8,8a-octahydronapthalen-2-ol
chamazulene
bisabolol oxide A
unidentified
benzyl benzoate
1-octadecyne*
(E)-2-(2,4-hexadiynylidene)-1,6-dioxaspiro[4,4]non-3-ene
(Z)-2-(2,4-hexadiynylidene)-1,6-dioxaspiro[4,4]non-3-ene
1-phenylbicyclo[3.3.1]nonan-9-one*

1098
1108
1141
1147
1164
1168
1175
1240
1291
1359
1381
1426
1459
1463
1470
1473
1482
1493
1500
1506
1513
1522
1529
1560
1585
1592
1595
1600
1613
1619
1636
1636
1650

0.2
4.6
0.1
t
0.1
0.3
2.8
0.2
75.8
0.1
0.5
0.2
2.9
0.2
0.1
0.1
1.4
0.1
0.4
0.1
0.1
0.4
0.4
0.1
0.3
0.1
0.3
0.1
0.2
0.2
t
0.1
0.1

1653
1659
1662
1669

0.2
0.5
0.3
0.3

1683
1689

0.3
t

1694
1720
1754
1766
1776
1844
1887
1931
1960

0.6
1.0
1.2
0.1
0.2
0.3
1.0
1.0
0.1

Note: components larger than 1% are highlighted in bold face; t = trace components
below 0.04% of oil; † = Kovats indices;
* = tentatively identified.

With reference to the Indian varieties reported, no bornyl acetate or
(-)-cis-chrysanthenol were detected in our study thereby confirming
that the major constituent of this Bhutanese variety of A. nubigena
was chemotype II. Notably, chamazulene, with a characteristic blue
color, was detected and isolated here as a new sub-chemotype for
the first time from this species.
The repeated purification of the EO and the crude MeOH extract
using column chromatography and preparative TLC resulted in the
isolation of eight major compounds (Fig. 1).
While (3R,6R)-linalool oxide acetate (1) [12], chamazulene (2) [13],
(E)-2-(2,4-hexadiynylidene)-1,6-dioxaspiro[4,4]non-3-ene (3) [12],
and (Z)-2-(2,4-hexadinylidene)-1,6-dioxaspiro[4,4]non-3-ene (4)
[12] were isolated from the EO component, 1-(4-hydroxyphenyl)propan-1-one (5) [14], oxyanin B (6) [15], luteolin (7) [1617] and the luteolin-7-O-β-D-glucopyranoside (8) [18] were
obtained from the crude MeOH extract component. They were
characterized from their MS, 1D and 2D-NMR spectroscopic data

and comparisons made with the data reported. Compound 6 lacked
complete NMR characterization and we have updated it here in the
experimental section.

Figure 1: The structures of isolated compounds 1-8.

The EO and the eight isolated compounds 1−8 were investigated for
their antiplasmodial, antimicrobial and cytotoxic activities. These
results, along with the positive controls and the bioassay data on the
crude MeOH, hexane, CH2Cl2 and CHCl3 extracts, which we
previously reported [6], are shown in Table 2. The EO exhibited
moderate antiplasmodial activities against Plasmodium falciparum
strains: TM4/8.2 (a wild type chloroquine and antifolate sensitive
strain) and K1CB1 (multidrug resistant strain). The antimalarial
activities of the crude extracts that we previously reported [6] were
almost seven fold more potent than that of EO. The EO also
displayed strong antibacterial activity against Bacillus subtilis (in
comparison to that of the standard, amoxicillin) and moderate
antifungal activity against Candida albicans with the minimum
inhibition zones (MIZ) of 13 mm and 11 mm, respectively.
Interestingly, while the (E)-spiroether (3), isolated from the EO,
displayed only moderate antiplasmodial activities, its isomeric form
(Z)-spiroether (4) demonstrated only selective antimicrobial
activities (Table 2).
Among the four flavonoid compounds tested for various
bioactivities (Table 2), compound 7 showed broad spectrum
activities against all subset of test organisms. It exhibited good
antimalarial activities against both the TM4/8.2 and K1CB1 strains
of P. falciparum with IC50 values of 6.2±1 µg/mL and 6.2±1 µg/mL,
respectively. It also demonstrated the highest cytoxicity against the
Vero and human oral carcinoma KB cells with the IC50 value of
14.5±7 µg/mL and 14.3±1 µg/mL, respectively.

Table 2: Bioactivities of the crude extractsa, EO and the pure compounds 1−8 isolated from A. nubegina

Antiplasmodial (IC50 in µg/mL)
Cytotoxicity (IC50 in µg/mL)
Antibacterial (MIZ* in mm)
Antifungal (MIZ* in mm)
Samples
TM4/8.2
K1CB1
VERO
KB
S. aureus B. subtilis S. epidermidis MRSA
C. albicans
a
MeOH extract
9.8±1
8.7±1
>10
>10
5
5
–
6.5
–
Hexane extracta
>12.5
6.2±3
>10
>10
5
5
–
5.5
–
CH2Cl2 extracta
>12.5
9.5±1
>10
>10
–
5
–
5.5
–
CHCl3 extracta
20.0±4
18.7±1
>25
>25
–
5.5
–
–
–
EO
66.1±2
70.6±5
>100
>100
–
13
–
–
11
>100
>100
>100
>100
–
8
–
–
5
1
>20
>20
>20
>20
Nt
Nt
Nt
Nt
Nt
2
7.3±2
8.8±1
>10
>10
–
7
–
–
5
3
>20
>20
>20
>20
–
11
8
–
5
4
>10
>10
>10
>10
Nt
Nt
Nt
Nt
Nt
5
>20
>20
>20
>20
–
–
–
–
–
6
6.2±1
6.2±1
14.5±2
14.3±2
8
7
10
10
5
7
2.8±1
2.0±1
33.2±4
>45
–
6
–
–
–
8
Chloroquineb
0.009
0.08
Cycloguanilb
0.009
0.8
Pyrimethamineb
0.02
7.7
Ellipticinec
0.09
Doxorubicinc
0.5
Amoxycillind
34
10
20
Vancomycind
15
Amphotericin Be
20
*MIZ: minimum inhibition zone with a well diameter of 4 mm. Nt: Not tested. −: Not active. a results reproduced from earlier report [12]. b Reference drugs for antiplasmodial
c
d
e
activity. Reference drugs for cytotoxicity and anticancer activities. Reference drugs for antibacterial activity. Reference drug for antifungal activity.

Compound 7 showed inhibitory activities against all Gram-positive
bacteria (B. subtilis, Staphylococcus aureus, methicillin resistant S.
aureus (MRSA), S. epidermidis) and fungi (C. albicans) with MIZ
values in the range of 5-10 mm (Table 2). These inhibitions were
significant when compared to that of the positive controls.
However, when the MIC values of this compound (including other
test samples) were determined, the best MIC-based activity
observed was 125 µg/mL against MRSA and S. epidermidis. While
the broad spectrum bioactivity of compound 7 implied that it could
be a general toxin, the literature confirmed that it was in fact a
common natural antioxidant flavone which had already been
extensively studied and was shown to have a better safety profile
[19]. Preclinical studies have shown that luetolin (7) possesses a
variety of bioactivities, including pro-oxidant, anti-inflammatory
and antimicrobial [20]. Further, its ability to inhibit angiogenesis, to
induce apoptosis, to prevent carcigenosis in animal models, to
reduce tumor growth in vivo and to sensitize tumor cells to the
cytotoxic effects of some anticancer drugs suggests that this
flavonoid has cancer chemopreventative and chemotherapeutic
potential [20]. Luetolin (7) has been previously studied and found
effective against leukemia, melanoma and carconomas of the
pancreas, ovary, brain, kidney, lung, colon and stomach [21]. Our
study demonstrated the cytoxicity of this compound against human
oral carcinoma KB cells.
In contrast to compound 7, its glycosylated analog 8 showed more
selectivity, being only active against a subset of the targets (Table
2). Compound 8 exhibited the best (among test samples) and highly
significant antimalarial activities with IC50 values of 2.8±1 µg/mL
and 2.0±1 µg/mL against TM4/8.2 and K1CB1 strains, respectively.
Its antimalarial activity is three fold more active than the parent
crude extracts (Table 2). Compound 8 also exhibited mild
cytotoxicty against the Vero cells with an IC50 value of 33.2±4
µg/mL but with no cytotoxicity to the human oral carcinoma KB
cells. An earlier study showed that this compound was not toxic to
RAW264.7 cells and also demonstrated that its aglycone luteolin (7)
was more toxic than the glycosylated form [22]. The fact that
cytotoxicity of compound 8 was lower than its aglycone 7, suggests
that glycosylation reduces cytotoxicity. This has been substantiated
by the fact that it is closely related derivatives, kaempferol and

quercetin, had higher toxicities compared to their glycosides [23].
Higher lipophilicity facilitates greater penetration into the lipid
membrane of organisms and therefore greater cytotoxicity which
explains the higher toxicity of compound 7 compared to its
glycosylated compound 8. This compound 8, with significant
antimalarial activities and lesser cytotoxicity, would serve as a
potential lead for developing an analogue with a better antimalarial
therapeutic index.
In conclusion, our study found that the Bhutanese variety of A.
nubigena contained: a) an essential oil (0.7% w/w) with (3R,6R)linalool oxide acetate as the major constituent (75.8%) (chemotype
II) and chamazulene as the new sub-chemotype; b) luteolin (7) as
the major marker compound of the crude MeOH extract which
exhibited a broad range of moderate antiplasmodial, cytoxicity and
antimicrobial activities; and c) compound 8 which showed
significant in vitro antiplasmodial activity with mild cytotoxicity
which was identified as a potential antimalarial scaffold. The in
vitro antimicrobial and cytotoxicity activities of the crude extracts,
EO and compounds 1, 3-4, and 7- 8 were supportive of the use of
this plant in BTM as a vulnerary, expectorant and for treating
abcess, swelling and tumors [6].
Experimental
Plant material: A. nubegina, is a perennial flowering herb of 30 cm
tall with slender fibrous roots and yellow flowers. It grows in alpine
mountain rocky slopes and sandy grounds of Bhutan at an elevation
range of 3600–4800 meters above sea level [24]. The aerial parts of
wild A. nubegina were collected from Lingzhi in Bhutan in August
2009. The collected plant material was air-dried and a herbarium
specimen with voucher number 73 was deposited at the herbarium
of the PRU, Thimphu, Bhutan.
Extraction of EO and crude methanol extract: The pale green
pleasantly aromatic EO (7 mL) was obtained by hydro-distillation
(temperature at 60 °C) of 1 kg of dried plant material using a
Clevenger apparatus for three hours. The EO collected was dried
over anhydrous magnesium sulphate. Alternatively, air-dried plant
material (2 kg) was chopped into small pieces and was repeatedly
extracted with methanol (AR/HPLC grade, 5 × 3 L over 48 h). The

4

extract was filtered and then concentrated using a rotary evaporator
to afford the crude methanol extract (58.22 g).
Analysis of EO using GC and GC-MS: The EO was analysed for its
chemical constituents using GC and GC-MS systems. The GC
analysis was performed on a Shimadzu GC-2010 Plus gas
chromatograph. Hydrogen was used as carrier gas (1.5 mL/min at
40 °C in a constant total flow mode) and the separation was
achieved using a Restek fused silica capillary column (Rxi-5MS: 30
m × 0.25 mm i.d., 0.25 µm film thickness). Injector and detector
temperature were set at 260 °C and 300 °C, respectively. The
starting oven temperature was programmed at 40 °C with an
increasing temperature of 6 °C/min until it reached to 290 °C.
Kovats retention indices (KI) were obtained by GC-FID analysis of
an aliquot of the EO spiked with an n-alkane mixture (C7 to C30).
The GC-MS analysis was performed using Shimadzu QP5050A
GC-MS system (electron impact (EI) mode at 70 eV). The column
and the GC-MS chromatographic conditions were same as that for
GC but He was used as carrier gas. The EO constituents were
identified by comparing mass spectra with NIST and NISTREP
mass spectra library of GC-MS data system and further confirmed
by comparing their Kovats indices (KI) with those reported [8, 1112, 25]. About 53 component peaks were detected and 44 of them
have been identified through MS library matching and KI
comparison techniques.
Isolation of compounds from EO and methanol extract: A rotary
evaporator was used for solvent evaporation under reduced pressure
at 35 °C – 50 °C. Flash column chromatography packed with Merck
Kieselgel 60 PF254 and the pre-coated silica plates (0.2 mm silica
thickness, Merck) were used for separation and purification of
compounds. UV light (short wavelength of 254 nm, long
wavelength of 366 nm) and ceric ammonium molybdate (CAM)
were used for visualization and detection of the compounds on TLC
plates. Micromass Waters Platform LCZ (single quadrupole, MeOH
as solvent) was used for obtaining the LR-ESI-MS. Shimadzu
GCMS-QP-5050 was used for recording the LR-EI-MS by the
direct insertion technique (at 70 eV). Micromass Waters Q-ToF
Ultima (quadrupole time-of-flight) mass spectrometer was used for
acquiring HR-ESI-MS. A 500 MHz Varian Unity Inova, 500 MHz
Varian Premium Shield (VNMRS PS 54), and 300 MHz Varian
Mercury spectrometer were used for obtaining the 1D and 2D-NMR
spectra using deuterated solvents depending upon the solubility of
compounds. The known compounds were identified through MS
library matching techniques (NIST and NISTREP mass spectra
library) and then confirmed through comparison of their optical
rotation, MS and NMR spectra with those reported in the relevant
literature.
The repeated purification of the EO (5.6 ml) using column
chromatography, preparative TLC and reverse phase (RP) silicacoated preparative TLC resulted in the isolation of four compounds
as: (3R,6R)-linalool oxide acetate (1), chamazulene (2), (E)-2-(2,4hexadiynylidene)-1,6-dioxaspiro[4,4]non-3-ene (3) and (Z)-2-(2,4hexadinylidene)-1,6-dioxaspiro[4,4]non-3-ene (4).

Subsequently, the MeOH extract (70.12 g) was fractionated with
hexane followed by ethyl acetate. Two fractionated extracts were
concentrated resulting into hexane extract (28 g) and the ethyl
acetate extract (12.5 g). The silica gel column chromatography
seperation yielded 17 fractions (AN-1 to AN-17). Seperation of
fraction AN-4 using silica-coated preparative TLC plates with a
mobile phase of H2O (20%):MeOH (80%) yielded 1-(4hydroxyphenyl)propan-1-one (5) and oxyanin B (6). Fractional
crystallization of AN-8 with MeOH/CHCl3 yielded crystal
compound luteolin (7). Purification of fraction AN-14 using RP
silica gel column chromatography with an isocratic mobile phase of
100% MeOH furnished luteolin-7-O-β-D-glucopyranoside (8).
Oxyanin B (6)
1
H NMR (500 MHz, DMSO-d6): 6.52 (1H, s, H-8), 6.94 (1H, d, J =
8.5 Hz, H-3′), 7.54 (1H, d, J = 8.5 Hz, H-2′), 7.61 (1H, s, H-6′),
3.49 (1H, bs, C(6)-OH), 12.73 (1H, bs, C(5)-OH), 3.73 (3H, s, C(7)OMe), 3.77 (3H, s, C(3)-OMe), 3.83 (3H, s, C(4′)-OMe).
13
C NMR (125 MHz, DMSO-d6): 55.7 (C(4′)-OMe), 59.7 (C(3)OMe), 59.8 (C(7)-OMe), 94.2 (C-8), 104.3 (C-10), 112.0 (C-6′),
115.6 (C-3′), 120.8 (C-1′), 122.1 (C-2′), 131.3 (C-7), 137.3 (C-3),
147.4 (C-4′), 149.7 (C-5′), 151.7 (C-6), 152.2 (C-5), 155.2 (C-2),
177.9 (C-4).
Bioassays: The EO and compounds 1-8 were tested in vitro for their
antiplasmodial, antimicrobial and the cytotoxicity activities using
the standard test protocols as described by us previously [12].
For antimalarial testing a multidrug resistant K1CB1 strain and a
wild type chloroquine and antifolate sensitive TM4/8.2 strain of
Plasmodium falciparum were used in the Microdilution
Radioisotope Technique. Chloroquine (Sigma), pyrimethamine
(Sigma) and cycloguanil were used as reference drugs for both the
plasmodial strains.
For the antimicrobial assay, the test organisms including
Escherichia coli (ATCC 25922), Bacillus subtilis (ATCC 6633),
Staphylococcus aureus (ATCC 6538), methicillin resistant S.
aureus (MRSA), (DMST 20651), Staphylococcus epidermidis
(ATCC 12228), Vibrio cholerae (DMST 2873) and Candida
albicans (ATCC 10231) were used. Amphotericin B (SigmaAldrich, USA), vancomycin (Edicin, Slovenia) and amoxicillin
(GPO, Thailand) were used as a reference drugs.
For the cytotoxicity assay, normal vero cells from kidney of African
green monkey, Cecopithecus aethiops and the human oral
carcinoma KB cells were used. Ellipticine and doxorubicin were
used as reference drugs.
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